| Literature DB >> 24627794 |
Varsha K Khodiyar1, Doug Howe2, Philippa J Talmud1, Ross Breckenridge3, Ruth C Lovering1.
Abstract
For the majority of organs in developing vertebrate embryos, left-right asymmetry is controlled by a ciliated region; the left-right organizer node in the mouse and human, and the Kuppfer's vesicle in the zebrafish. In the zebrafish, laterality cues from the Kuppfer's vesicle determine asymmetry in the developing heart, the direction of 'heart jogging' and the direction of 'heart looping'. 'Heart jogging' is the term given to the process by which the symmetrical zebrafish heart tube is displaced relative to the dorsal midline, with a leftward 'jog'. Heart jogging is not considered to occur in mammals, although a leftward shift of the developing mouse caudal heart does occur prior to looping, which may be analogous to zebrafish heart jogging. Previous studies have characterized 30 genes involved in zebrafish heart jogging, the majority of which have well defined orthologs in mouse and human and many of these orthologs have been associated with early mammalian heart development. We undertook manual curation of a specific set of genes associated with heart development and we describe the use of Gene Ontology term enrichment analyses to examine the cellular processes associated with heart jogging. We found that the human, mouse and zebrafish 'heart jogging orthologs' are involved in similar organ developmental processes across the three species, such as heart, kidney and nervous system development, as well as more specific cellular processes such as cilium development and function. The results of these analyses are consistent with a role for cilia in the determination of left-right asymmetry of many internal organs, in addition to their known role in zebrafish heart jogging. This study highlights the importance of model organisms in the study of human heart development, and emphasises both the conservation and divergence of developmental processes across vertebrates, as well as the limitations of this approach.Entities:
Year: 2013 PMID: 24627794 PMCID: PMC3931453 DOI: 10.12688/f1000research.2-242.v2
Source DB: PubMed Journal: F1000Res ISSN: 2046-1402
Proteins included in zebrafish ‘jogging’ gene list and the human and mouse ‘jogging ortholog’ gene lists.
The evidence for these 30 zebrafish proteins having a role in heart jogging comes from mutant, morpholino or functional complementation studies, as described in the associated publications.
|
|
|
|
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| no mammalian orthologs | |
Comparison of enriched Gene Ontology terms across orthologous gene lists from zebrafish, human and mouse.
The enriched GO terms were grouped into specific ontology areas, with a selection of more specific child term (preceded with a dash) also included. The full list of grouped GO terms can be found in Table S4, which also shows the genes annotated to each term from each of the three species. k: the number of genes in each gene list annotated to the GO term; M: the number of genes in the species proteome annotated to the GO term.
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
|
| |||||||||
| GO:0032502 developmental process | 30 | 2357 | 1.3% | 24 | 6803 | 0.4% | 22 | 3945 | 0.6% |
| - GO:0009888 tissue development | 30 | 673 | 4.5% | 17 | 1849 | 0.9% | 14 | 1138 | 1.2% |
| - GO:0072358 cardiovascular system development | 30 | 487 | 6.2% | 15 | 1095 | 1.4% | 10 | 679 | 1.5% |
| - GO:0001944 vasculature development | - | - | - | 7 | 666 | 1.1% | 7 | 436 | 1.6% |
| - GO:0007507 heart development | 30 | 268 | 11.2% | 13 | 634 | 2.1% | 8 | 390 | 2.1% |
| - GO:0001947 heart looping | 22 | 83 | 26.5% | 7 | 68 | 10.3% | - | - | - |
| - GO:0007399 nervous system development | 8 | 700 | 1.1% | 15 | 2802 | 0.5% | 12 | 1486 | 0.8% |
| - GO:0072001 renal system development | 6 | 100 | 6.0% | 9 | 386 | 2.3% | 6 | 200 | 3.0% |
| - GO:0007423 sensory organ development | - | - | - | 10 | 738 | 1.4% | 8 | 480 | 1.7% |
| - GO:0048736 appendage development | 4 | 123 | 3.3% | 4 | 237 | 1.7% | 4 | 159 | 2.5% |
| - GO:0050793 regulation of developmental process | 6 | 267 | 2.2% | 14 | 2383 | 0.6% | 14 | 1542 | 0.9% |
|
| |||||||||
| GO:0007389 pattern specification process | 30 | 435 | 6.9% | 15 | 644 | 2.3% | 12 | 414 | 2.9% |
| - GO:0009799 specification of symmetry | 30 | 177 | 16.9% | 10 | 147 | 6.8% | 7 | 90 | 7.8% |
| - GO:0061371 determination of heart left/right
| 30 | 97 | 30.9% | 8 | 71 | 11.3% | 4 | 48 | 8.3% |
|
| |||||||||
| GO:0071840 cellular component organization or
| 12 | 1124 | 1.1% | 17 | 5991 | 0.3% | 15 | 3306 | 0.5% |
| - GO:0030030 cell projection organization | 10 | 274 | 3.6% | 12 | 1311 | 0.9% | 11 | 644 | 1.7% |
| - GO:0051128 regulation of cellular component
| - | - | - | 10 | 1894 | 0.5% | 10 | 1293 | 0.8% |
| - GO:0031344 regulation of cell projection organization | - | - | - | 5 | 452 | 1.1% | 5 | 311 | 1.6% |
| GO:0006468 protein phosphorylation | 8 | 696 | 1.1% | 8 | 842 | 1.0% | 9 | 748 | 1.2% |
| - GO:0001932 regulation of protein phosphorylation | - | - | - | 8 | 1124 | 0.7% | 8 | 722 | 1.1% |
| GO:0006357 regulation of transcription from RNA
| 8 | 166 | 4.8% | 10 | 1939 | 0.5% | 12 | 1268 | 0.9% |
| GO:0042127 regulation of cell proliferation | 5 | 70 | 7.1% | 9 | 1769 | 0.5% | 9 | 1123 | 0.8% |
| GO:0007049 cell cycle | - | - | - | 9 | 1644 | 0.5% | 8 | 915 | 0.9% |
| - GO:0051726 regulation of cell cycle | - | - | - | 6 | 934 | 0.6% | 6 | 538 | 1.1% |
|
| |||||||||
| GO:0023052 signaling | 12 | 2131 | 0.6% | 16 | 6682 | 0.2% | 16 | 4568 | 0.4% |
| - GO:0023051 regulation of signaling | 7 | 521 | 1.3% | 16 | 3227 | 0.5% | 16 | 1931 | 0.8% |
| GO:0050896 response to stimulus | - | - | - | 20 | 10767 | 0.2% | 21 | 6679 | 0.3% |
| - GO:0048583 regulation of response to stimulus | 7 | 557 | 1.3% | 15 | 3799 | 0.4% | 15 | 2140 | 0.7% |
|
| |||||||||
| GO:0007017 microtubule-based process | 6 | 188 | 3.2% | 6 | 873 | 0.7% | 4 | 358 | 1.1% |
| GO:0040011 locomotion | 10 | 289 | 3.5% | 10 | 1448 | 0.7% | 8 | 753 | 1.1% |
| - GO:0040012 regulation of locomotion | - | - | - | 6 | 657 | 0.9% | 5 | 473 | 1.1% |
| - GO:2000145 regulation of cell motility | - | - | - | 6 | 608 | 1.0% | 5 | 439 | 1.1% |
| - GO:0016477 cell migration | 8 | 200 | 4.0% | 6 | 931 | 3.6% | 5 | 504 | 1.0% |
Figure 1. View of relationships between enriched terms from the cellular component organization or biogenesis ontology.
The GONUTs view of relationships between enriched terms from the cellular component organization or biogenesis ontology [84]. The grey arrows are used where a term has an ‘is a’ relationship to its parent term, the blue arrows indicate a ‘part of’ relationship. The bars below each GO term indicates which of these terms are enriched in the zebrafish ‘jogging’ gene list, and the human and mouse ‘jogging ortholog’ gene lists.
Figure 2. Venn diagrams describing the multiple roles of genes associated with heart development.
Venn diagrams showing the overlap between the GO terms associated with A) the zebrafish ‘heart jogging’ gene list (30 genes) and B) the mouse combined heart development gene list (103 genes).
Diseases associated with the human ‘jogging ortholog’ genes.
The associated diseases are described in the listed publications.
|
|
|
|
|---|---|---|
|
| - | Hereditary haemorrhagic telangiectasia type 2
|
|
| - | Familial adenomatous polyposis coli-1
[ |
|
| - | Microphthalmia, syndromic 6
[ |
|
| - | - |
|
| - | Pulmonary hypertension
[ |
|
| - | - |
|
| - | - |
|
| - | - |
|
| Dextrocardia,
| Ciliary dyskinesia, primary, 17
[ |
|
|
| Ciliary dyskinesia, primary, 15
[ |
|
| - | - |
|
| - | - |
|
|
| Ciliary dyskinesia, primary, 13
[ |
|
| - | Several craniosynostosis
[ |
|
| Ventricular septal defect
[ | - |
|
| - | - |
|
| - | - |
|
| - | - |
|
| - | - |
|
|
| Ciliary dyskinesia, primary, 19, Kartagener’s
|
|
| Cardiac septal defects (not confirmed as
| Cornelia de Lange syndrome 1
[ |
|
| - | Colorectal adenocarcinoma
[ |
|
|
| nephronophthisis type 3
[ |
|
| Dextrocardia,
| Polycystic kidney disease 2
[ |
|
| atrioventricular canal defects
[ | juvenile myelomonocytic leukemia
[ |
|
| - | - |